Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF REVENUE RECOGNITION (Details) (Parenthetical)

v3.24.3
SCHEDULE OF REVENUE RECOGNITION (Details) (Parenthetical) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Product Information [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,350,386 $ 298,484 $ 7,154,429 $ 319,143
Health Care, Patient Service [Member]        
Product Information [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax [1]     6,259,806 $ 248,654
Health Care, Patient Service [Member] | CyPath Lung [Member]        
Product Information [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax     $ 332,000  
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $332,000 and $24,000 for the nine months ended September 30, 2024 and 2023.